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The main antivirals employed to combat seasonal and pandemic inﬂuenza are oseltamivir and zanamivir
which act by inhibiting the virus-encoded neuraminidase. These have to be deployed close to the time of
infection and antiviral resistance to the more widely used oseltamivir has arisen relatively rapidly. Defec-
tive interfering (DI) inﬂuenza virus is a natural antiviral that works in a different way to oseltamivir and
zanamivir, and a cloned version (segment 1 244 DI RNA in a cloned A/PR/8/34 virus; 244/PR8) has proved
effective in preclinical studies in mice. The active principle is the DI RNA, and this is thought to interact
with all inﬂuenza A viruses by inhibiting RNA virus synthesis and packaging of the cognate virion RNA
into nascent DI virus particles. We have compared the ability of DI virus and oseltamivir to protect ferrets
from intranasal 2009 pandemic inﬂuenza virus A/California/04/09 (A/Cal, H1N1). Ferrets were treated
with a single 2 lg intranasal dose of 244 DI RNA delivered as 244/PR8 virus, or a total of 25 mg/kg body
weight of oseltamivir given as 10 oral doses over 5 days. Both DI virus and oseltamivir reduced day 2
infectivity and the inﬂux of cells into nasal ﬂuids, and permitted the development of adaptive immunity.
However DI virus, but not oseltamivir, signiﬁcantly reduced weight loss, facilitated better weight gain,
reduced respiratory disease, and reduced infectivity on days 4 and 6. 244 DI RNA was ampliﬁed by
A/Cal by >25,000-fold, consistent with the amelioration of clinical disease. Treatment with DI virus did
not delay clearance or cause persistence of infectious virus or DI RNA. Thus in this system DI virus
was overall more effective than oseltamivir in combatting pandemic A/California/04/09.
 2012 Elsevier B.V. Open access under CC BY license. 1. Introduction
Defective interfering (DI) viruses are natural mutants that arise
spontaneously, occur widely, and have a genome that has under-
gone at least one major deletion. As a result their replication is
dependent on complementation by a genetically compatible infec-
tious helper virus to provide any missing function. All DI genomes
retain sequences that allow them to be packaged and replicated.
The resulting DI virus particle is usually indistinguishable from
that of the infectious virus. In cell culture DI viruses are not only
defective but also interfering, the DI genome being the structure
responsible for this property. Thus, under appropriate conditions,
the presence of the DI genome reduces the amount of infectious
progeny virus produced (Holland, 1990a,b; Huang and Baltimore,
1970; Nayak et al., 1989; Perrault, 1981). Some, but not all DI
viruses can protect animals from clinical disease caused by the: +44 2476523568.
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 license. homologous virus (Barrett and Dimmock, 1986; Dimmock, 1991,
1996; Dimmock et al., 2008; Roux et al., 1991). Inﬂuenza DI 244
virus also protects against genetically unrelated (heterologous)
viruses (pneumonia virus of mice (PVM: Paramyxoviridae and inﬂu-
enza B virus) in vivo, primarily by induction of type 1 interferon
(Easton et al., 2011; Scott et al., 2011b). DI virus-induced interferon
is not required for protection against a lethal challenge with inﬂu-
enza A viruses (Easton et al., 2011).
Inﬂuenza A DI viruses were the ﬁrst to be described (von Mag-
nus, 1954) and have been studied extensively (Nayak, 1980; Nayak
et al., 1985, 1989). However, most DI inﬂuenza virus preparations
contain many different defective RNA sequences, so that it was not
possible to determine the relationship between a particular defec-
tive RNA sequence and its biological properties. Recently we solved
this problem using reverse genetics to make cloned DI viruses that
contain one major species of DI RNA (Dimmock et al., 2008; Duhaut
and Dimmock, 1998, 2000, 2002, 2003). One such inﬂuenza virus,
containing the 244 DI RNA, derived from segment 1, strongly pro-
tected mice against disease caused by several different inﬂuenza A
virus subtypes when inoculated intranasally (Dimmock et al.,
2008). This protection is dependent on the integrity of the 244 DI
N.J. Dimmock et al. / Antiviral Research 96 (2012) 376–385 377RNA and protection is lost when the DI RNA is destroyed by exten-
sive UV irradiation. The DI inﬂuenza A virus particle retains recep-
tor speciﬁcity and, when topically applied, targets the DI RNA to
inﬂuenza virus-susceptible cells in the respiratory tract. In this
way the virus particle provides a highly speciﬁc delivery system.
We have shown that non-cloned and cloned DI inﬂuenza A
viruses protect mice from lethal infection caused by inﬂuenza A
virus (Dimmock et al., 1986, 2008; Morgan et al., 1993; Noble
and Dimmock, 1994). Only a single dose of cloned 244/PR8 virus
is needed and the DI RNA is ampliﬁed by the infecting virus (Scott
et al., 2011a). Protection lasts for one to several weeks depending
on the initial dose of DI virus (Dimmock et al., 2008; Scott et al.,
2011a). Post-infection treatment is effective for up to 2 days after
infection (Dimmock et al., 2008).
Inﬂuenza viruses usually have to be adapted to grow in mice
whereas the ferret is highly susceptible to new human isolates
(Francis, 1934; Shope, 1931; Smith et al., 1933). Because humans
and ferrets develop a very similar disease the ferret is the preferred
model for human inﬂuenza (Barnard, 2009; Cameron et al., 2008;
Herlocher et al., 2001; Matsuoka et al., 2009; Smith and Sweet,
1988; van den Brand et al., 2010; Whitley, 2010). In a preliminary
study in ferrets we tested a non-cloned DI inﬂuenza virus prepara-
tion that contained an unspeciﬁed collection of DI RNAs derived
from an equine inﬂuenza A virus, and showed that it afforded fer-
rets some protection against an H3N2 challenge virus (Mann et al.,
2006). More recently we used a cloned 244/PR8 virus (Dimmock
et al., 2008) reconstructed with a PR8 hemagglutinin variant that
bound to both a 2,6- and a 2,3-linked sialyl receptors (Meng
et al., 2010), so that DI RNA would be delivered to and protect cells
bearing both types of receptor. There are a number of studies of
pandemic H1N1 in ferrets (Itoh et al., 2009; Maines et al., 2009;
Munster et al., 2009; van den Brand et al., 2010). Pandemic 2009
H1N1 viruses differ from seasonal H1N1 viruses in a number of
ways: the former use 2,6- and 2,3-linked receptors (Childs et al.,
2009), preferentially infect the lower respiratory tract in humans
and in animal models (Guarner and Falcon-Escobedo, 2009), repli-
cate in the lower respiratory tract of ferrets rather than the nasal
cavity (Munster et al., 2009; van den Brand et al., 2010), and cause
more severe pathological lesions than seasonal H1N1 virus in mice,
ferrets and non-human primates (Itoh et al., 2009).
In addition to vaccines (Cox and Bridges, 2007; Nichol, 2008;
Treanor, 2004) antivirals directed against the virus neuraminidase
have become an important addition to the armoury providing relief
from inﬂuenza disease (Colman, 2009; Oxford, 2007; Smith et al.,
2006). The antivirals oseltamivir and zanamivir protect against
all inﬂuenza A and B strains (Jefferson et al., 2009). Oseltamivir, ta-
ken orally, and zanamivir, a nasal spray, are administered twice
daily, and are most effective when taken before or soon after infec-
tion. However, viruses are well-known for acquiring resistance,
and oseltamivir-resistant mutants, already wide-spread in sea-
sonal pre-2009 pandemic H1N1 virus (Hauge et al., 2009; Meijer
et al., 2009), are now appearing in the 2009 pandemic virus (Duan
et al., 2010; Hamelin, 2010; Ujike et al., 2011). New broad-spec-
trum counter-measures, which do not result in virus resistance,
are urgently required.
Oseltamivir was preclinically tested in ferrets and these animals
are the preferred model for studying study new viruses and inves-
tigating oseltamivir-resistant strains (Boltz et al., 2008; Govorkova
et al., 2006, 2011; Hamelin et al., 2010; Herlocher et al., 2004; Itoh
et al., 2009; Mendel et al., 1998). Thus we have used this model to
compare the protective abilities of cloned DI 244/PR8 and oseltam-
ivir. Data presented here show that a single intranasal dose of 2 lg
of DI RNA is overall more effective than 10 doses of 2.5 mg/kg
bodyweight administered twice daily over ﬁve days (25 mg/kg in
total) of oseltamivir at ameliorating the effects of pandemic inﬂu-
enza virus A/California/04/09 (H1N1).2. Materials and methods
2.1. Ferret studies
Ferret work was conducted according to UK Home Ofﬁce legis-
lation and was approved by the local ethical committee. Thirty out-
bred male ferrets (Mustela putorius furo), 3–4 months of age,
weighing 860–1367 g (mean 1082 g), were obtained from Highgate
Farm, UK. They were seronegative for antibodies to A/Cal as deter-
mined by haemagglutination-inhibition. Ferrets were separated
into 4 groups each comprising ﬁve animals: groups were treated
intranasally with +300 lg active 244 DI virus and infected with
A/Cal 2 h later, treated with oseltamivir by oral gavage (see below)
and infected with A/Cal 2 h later, infected with A/Cal, and inocu-
lated with saline. An identiﬁer chip (idENTICHIP, Bio-Thermo)
was inserted subcutaneously into the scruff of each animal. Ferrets
receiving 244 DI virus (see below) were sedated by isoﬂurane inha-
lation before intranasal delivery of 500 ll (250 ll per nostril) of a
single dose of 2 lg of 244 RNA in 300 lg of carrier virus. Ferrets
receiving oseltamivir treatment were given 2.5 mg/kg bodyweight
administered by oral gavage twice-daily every twelve hours (5 mg/
kg bodyweight/day) over a period of ﬁve days as used by others
(Govorkova et al., 2007; Hurt et al., 2010), which is comparable
to an oral prophylactic human dose of 75 mg/kg bodyweight/day
(Ward et al., 2005). Oseltamivir phosphate was acquired as osel-
tamivir powder (Roche) for oral suspension and was reconstituted
with sterile water to a ﬁnal concentration of 12 mg/ml. The volume
of oseltamivir solution required for each ferret was calculated from
the weight of each ferret recorded each morning on the day of
administration. This oseltamivir dose and schedule protected fer-
rets from the highly virulent H5N1 virus (A/Vietnam/1023/04)
when administered at 4 h after infection and then twice daily for
5 days (Govorkova et al., 2007). Two hours after intranasal admin-
istration of 244 RNA and the ﬁrst oseltamivir dose, ferrets were se-
dated by intramuscular injection of ketamine (17.9 mg/kg) and
xylazine (3.6 mg/kg) then inoculated intranasally with 500 ll
(250 ll per nostril) of 100 TCID50 2009 inﬂuenza virus A/Califor-
nia/04/09 (A/Cal; H1N1). Solutions were prepared on the day of
challenge and the titre of the virus conﬁrmed by infectivity assay.
Control groups were infected with virus or inoculated with saline.
Rectal temperatures were measured daily. Ferrets were monitored
twice-daily post-challenge throughout the course of the study for
clinical signs of inﬂuenza infection (lack of activity, sneezing, nasal
discharge, lack of appetite, weight loss and pyrexia). Clinical signs
were scored as follows: loss of activity scored 0 for normal activity
levels, 1 for reduced activity, and 2 if inactive; nasal discharge
scored 0 for no discharge and 1 for a discharge; sneezing scored
0 for no sneezing, and 1 for sneezing; appetite was scored 0 for
no loss of appetite, and 1 for loss of appetite. Nasal washes were
collected from each ferret following ketamine and xylazine seda-
tion (as above) at days 1–6 and then at days 8, 10 12 and 14
post-challenge. For each nasal wash, 2 ml of PBS were instilled
by small multiple volumes into each nasal cavity with expectorate
collected into a beaker. The study was terminated at 14 days post-
challenge.2.2. Production of cloned 244 DI virus by reverse genetics
244 DI RNA was generated spontaneously during the transfec-
tion of 293T cells with plasmids to make infectious inﬂuenza A/
PR/8/34 (Dimmock et al., 2008; Subbarao et al., 2003). The
haemagglutinin (HA) protein of the original 244/PR8 virus had a
preference for cell receptors comprising a2,3-linked sialyl receptor
sequences, so we reconstructed 244 DI virus with the HA protein
of a PR8 virus that binds to both a2,6- and a2,3-linked sialyl
Fig. 1. Changes in weight of A/Cal/04/09-infected ferrets given one dose of 244 DI virus at 2 h before infection (solid arrow) or 10 treatments with oseltamivir (open arrows)
also given at 2 h prior to infection (stippled arrow) and then twice daily over 5 days. Ferrets (n = 5) were treated on day 0 and infected 2 h later. Each arrow represents one
treatment. The data show the mean group body weight changes expressed as a percentage change compared to the group average weight at day 0 (a) The mean group weight
loss in infected ferrets was reduced on day 3 by 244 DI virus and by oseltamivir (circled); means ± SD are inset. Only 244 DI virus had a signiﬁcant effect (see panel b). j, A/
Cal + 244 DI virus; N, A/Cal + oseltamivir; , A/Cal;s, saline. Data from individual animals and the results of statistical analysis using a one tailed unpaired t-test for data from
days 3 and 4 post infection is shown in panel (b). 244 DI virus-treated infected ferrets lost signiﬁcantly less weight than untreated infected ferrets on days 3 and 4. The mean
weight change of oseltamivir-treated, infected ferrets did not differ signiﬁcantly from that of untreated infected ferrets on days 3 and 4.
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Fig. 2. Temperatures in A/Cal-infected ferrets given a single treatment of 244 DI virus (solid arrow) or 10 treatments with oseltamivir (open arrows). (a) Temperatures over
the period of the study. Infection is denoted by a stippled arrow. The key region of temperature elevation on day 3 is circled. (b) Details of the temperatures of individual
animals on day 3 are shown with standard deviations. Other data are as in Fig. 1. Animals (n = 5) were anaesthetised and rectal temperatures taken prior to any other
procedure. j, A/Cal + 244 DI virus; N, A/Cal + oseltamivir; , A/Cal; s, saline.
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cells bearing both types of receptor, and thus protect against infec-
tious viruses which recognise either type of receptor as described
previously (Meng et al., 2010). The resulting mixture of 244/PR8
DI virus and infectious helper A/PR8 virus was puriﬁed by pelleting
through sucrose. Stocks were resuspended in PBS, standardized by
haemagglutination titration, and stored in liquid nitrogen. All DI
virus stocks were tested for their ability to protect mice as
described previously (Dimmock et al., 2008) prior to their use in
ferrets (data not shown). Before inoculation into animals, helper
virus infectivity was eliminated with a short burst (50 s) of UV
irradiation at 253.7 nm (0.64 mW/cm2). This is referred to as ‘ac-
tive DI virus’. The UV inactivation target is viral RNA, and UV has
little effect on the DI RNA because of its small target size, 395 nt
compared with 13,600 nt for infectious virus. The absence of infec-
tivity after UV-irradiation was checked by infectivity assay (see
Section 2.4) and by intranasal inoculation into mice (Dimmock
et al., 2008).2.3. PCR assays
RNA was extracted from nasal washes with a QIAamp mini RNA
kit (Qiagen), and quantitative real time PCR performed to quanti-
tate virion-sense RNA using an ABI prism 7000. The following
primers and probe were used: 244 1F (50 CTCTTTGCCCAGAATGAG-
GAAT 30), 244 1R (50 CATAATCAAGAAGTACACATCAGGAAGAC 30)
and probe (50 FAM-CCCTCAGTCTTCTCC 30). Primers were synthe-
sized by Invitrogen, and the probes by ABI. Reverse transcriptase
reactions (10 ll) were performed using 6 ll extracted RNA, Revert-
Aid reverse transcriptase and random hexamer (Fermentas)
according to the manufacturer’s instructions. cDNA (1 ll) was used
in 20 ll of PCR reaction. A virion-sense 244 RNA standard was
made by subcloning PCR products of full length 244 RNA in
pGEMT-easy vector (Promega). RNA was transcribed using the T7
polymerase (MEGAscript, Ambion), the mix was digested with
DNase I, and RNA puriﬁed by electro-elution. After ethanol precip-
itation, RNA was resuspended into RNase-free water and quanti-
Fig. 3. A single treatment with 244 DI virus, but not 10 treatments with oseltamivir,
signiﬁcantly reduced respiratory disease (sneezing and nasal discharge) in infected
ferrets. Data collected over 14 days were analysed. The values are the occurrence of
sneezing and nasal discharge events in each group over the 14 days of observation.
The scores were assigned 10% for each individual event, so that if all ﬁve ferrets
were positive for both sneezing and nasal discharge they would score 100%. Zero is
only scored when the other group was positive. Statistical signiﬁcance was
determined with a one tailed Mann–Whitney U test.
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Standard curves were generated by performing 10-fold serial dilu-Table 1
Quantitation of cells in nasal washes: 244 DI virus and oseltamivir reduced the number o
Group Days relative to infection on day 0
4 1 2 3 4 5
A/Cal 4.7 ± 0.1 5.0 ± 0.2 6.0 ± 0.2 7.4 ± 0.3 7.0 ± 0.2 7.0 ±
244 DI virus + A/Cal 5.0 ± 0.2 4.8 ± 0.2 5.3 ± 0.2 7.1 ± 0.3 6.9 ± 0.4 6.9 ±
Oseltamivir + A/Cal 4.7 ± 0.2 5.0 ± 0.2 5.0 ± 0.3 6.3 ± 0.9 7.1 ± 0.4 7.1 ±
Saline 5.2 ± 0.3 4.9 ± 0.4 5.1 ± 0.2 4.9 ± 0.2 4.9 ± 0.2 4.8 ±
a Mean log10 cells per ferret ± SD; *a nasal wash was not carried out on this day; on da
different from the A/Cal group but not from each other.tions of known RNA copy numbers with each dilution assayed in
duplicate. The reaction was conducted at 50 C for 2 min, 95 C
for 10 min, then 40 cycles of 94 C for 15 s followed by 60 C for
1 min.
2.4. Infectivity assay
Nasal washes from each ferret were titrated for A/Cal infectivity
in a focus-forming assay using MDCK cells in 96-well plates in trip-
licate (Scott et al., 2011a). After infection cells were incubated at
33 C for 24 h, ﬁxed overnight at 4 C with 1:1 methanol:acetone,
and blocked with 5% w/v milk powder in PBS. Virus-positive cells
were detected using a mouse monoclonal antibody that recognises
the NP protein of inﬂuenza A viruses (9G8 Abcam), and a goat anti-
mouse IgG-alkaline phosphatase conjugate (Sigma), both in buf-
fered saline containing 0.1% v/v Tween, and ﬁnally incubated with
an alkaline phosphatase substrate (NBT/BCIP in TMN buffer; Sig-
ma). At least 50 stained cells (foci) at an appropriate dilution were
counted in each of three wells and averaged to give a titre in focus-
forming units (FFU) per ferret. Assays carried out on different days
were normalised to a standard A/Cal virus preparation. Variation in
the standard was less than 4-fold.
2.5. Haemagglutination-inhibition (HI) assay
Before assay sera were treated with receptor destroying enzyme
(RDE II (SEIKEN), Cosmos Biological) overnight at 37 C to remove
non-speciﬁc inhibitors of haemagglutination and then incubated
at 56 C for 30 min to destroy the enzyme. Serial 2-fold dilutions
of serum were incubated with 4 HAU of A/Cal for 1 h at ambient
temperature before adding chicken red blood cells (VLA, Wey-
bridge). The HI titre is expressed as the reciprocal of the dilution
of serum that causes 50% inhibition of agglutination, and is inter-
polated between full agglutination and no agglutination.
3. Results
3.1. 244 DI virus reduces weight more effectively than oseltamivir in
A/Cal-infected ferrets
Analyses of the weights of the animals and the percentage
weight changes relative to the weight on day 0 were carried out
with a repeated measures ANOVA. This was conducted on the data
for days 1 to day 8 post-infection, as these reﬂect the period during
which infectious virus was detected in nasal washes (see Sec-
tion 3.5). Data conﬁrm that infection signiﬁcantly affected weight
compared with non-infected animals throughout the 8 day period
(p < 0.05). The data also show a single treatment of infected ferrets
with 244 DI virus resulted in a greater overall weight gain that was
seen with the infected control animals (p < 0.05). This indicates
that while the treated animals experienced a transient weight loss
on day 3 (Fig. 1a), this was less than was seen with the infected
control group, and that treated animals subsequently gained
weight at a greater rate than did the control infected animals. In
contrast the repeated measures ANOVA showed that while multi-f cells in nasal washes in A/Cal infected ferrets on days 2 and 3.a
6 7 8 9 10 11 12 13 14
0.1 7.2 ± 0.1 ⁄ 6.8 ± 0.2 ⁄ 6.7 ± 0.2 ⁄ 6.5 ± 0.2 ⁄ 6.0 ± 0.5
0.4 7.2 ± 0.2 ⁄ 6.6 ± 0.3 ⁄ 6.7 ± 0.2 ⁄ 6.4 ± 0.3 ⁄ 5.7 ± 0.5
0.3 7.2 ± 0.1 ⁄ 7.1 ± 0.2 ⁄ 6.9 ± 0.3 ⁄ 6.8 ± 0.1 ⁄ 6.1 ± 0.3
0.2 4.8 ± 0.1 ⁄ 4.8 ± 0.2 ⁄ 4.8 ± 0.2 ⁄ 4.8 ± 0.3 ⁄ 4.9 ± 0.1
ys 2 and 3 the 244 DI virus- and oseltamivir-treated groups (bold) were signiﬁcantly
Fig. 4. A/Cal infectivity in nasal washes of infected ferrets given a single treatment with 244 DI virus (solid arrow) or 10 treatments with oseltamivir (open arrows). Time of
infection is denoted by the stippled arrow. Infectivity titres were titrated in MDCK cells (a). The limit of sensitivity of the assay was 1.92 log10 FFU/ml (dotted line).
j, A/Cal + 244 DI virus; N, A/Cal + oseltamivir; , A/Cal;s, saline. Panel b: on day 2, 244 DI virus and oseltamivir signiﬁcantly reduced virus infectivity by 62-fold and 200-fold
respectively (one-tailed Mann–Whitney U test) (⁄⁄in panel a). Panel c: on day 4 infectivity was signiﬁcantly lower (5.9-fold) in 244 DI virus-treated ferrets (mean 4.03 log10)
on day 4 than in oseltamivir-treated ferrets (mean 4.8 log10) (## in panel a). Panel d (left): on day 6 infectivity was signiﬁcantly higher (105-fold) in oseltamivir-treated
infected ferrets (mean 5.38 log10) than in 244 DI virus-treated infected animals (3.37 log10), or 123-fold higher than in control infected animals (mean 3.29 log10) (panel d
right, and §§in panel a).
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Fig. 5. Ampliﬁcation of 244 DI RNA in nasal washes taken from A/Cal-infected ferrets given a single treatment with 244 DI virus (solid arrow) or 10 treatments with
oseltamivir (open arrows). Time of infection is denoted by the stippled arrow. The total amount of 244 DI RNA present in each nasal wash was determined by quantitative
RT-PCR. The dotted line shows the limit of detection. (a) Mean 244 RNA copy numbers for each ferret group (n = 5). j, A/Cal + 244 DI virus; N, A/Cal + oseltamivir; ., A/Cal;
D, saline. (b) 244 DI RNA values for individual ferrets.
382 N.J. Dimmock et al. / Antiviral Research 96 (2012) 376–385ple (10) treatments with oseltamivir resulted in a reduced weight
loss when compared with the infected control group (Fig 1a), this
was not signiﬁcant at the 5% level. The repeated measures ANOVA
identiﬁed day 3 post-infection as the time at which the greatest
difference between either of the two treatments and the control in-
fected group occurred, with DI virus providing the more effectiveTable 2
HI serum antibody determined before infection and at 14 days after infection.a
Treatment and inoculum HI titre on
Day 0 Day 14
244 DI virus + A/Cal <47 8280 ± 2696
p = 0.008
Oseltamivir + A/Cal <47 4533 ± 593 p = 0.22
p = 0.095
A/Cal <47 6666 ± 3772
Saline <40 <47
a The HI titre (± SD) is the reciprocal of the serum dilution giving 50% inhibition of
haemagglutination. Signiﬁcance was determined using a two tailed Mann–Whitney
U test. The HI titres of ferrets given 244 DI virus +A/Cal and A/Cal alone were not
signiﬁcantly different on day 14 (p = 0.22).amelioration of weight loss. Separate analysis of data using a one
tailed unpaired t test was in agreement with the repeated mea-
sures ANOVA. The t-test showed that a single treatment with
244 DI virus at 2 h prior to infection signiﬁcantly protected ferrets
from A/Cal-associated weight loss on days 3 and 4 (Fig. 1b). By t-
test oseltamivir, given at 2 h prior to infection and overall twice
daily for 5 days, did not signiﬁcantly reduce weight loss compared
to the untreated infected group on days 3 and 4 (Fig. 1b).
3.2. 244 DI virus and oseltamivir reduce fever in A/Cal-infected ferrets
Fig. 2a shows the mean daily temperatures for the groups of fer-
rets following infection. Control A/Cal-infected ferrets developed a
pronounced fever spike at 3 days after infection (circled). Fever
was reduced by both 244 DI virus and oseltamivir treatments.
Though the reduction in temperature on day 3 post infection with
either treatment was clearly evident, neither was statistically sig-
niﬁcant at the 95% level (p = 0.09 and p = 0.07 for treatment with
244 DI virus or oseltamivir treatment, respectively). This was due
to one ferret in the control A/Cal-infected group that recorded a
non-elevated temperature, as omission of this data point gave p
Table 3
Summary of protection of ferrets from A/Cal-mediated infection and disease using 244 DI virus or oseltamivir.






Reduction in loss of body weight compared with the
mock-treated infected group
Yes Yes No No Fig. 1
Subsequent weight gain compared with the
mock-treated infected group
Yes Yes No No Fig. 1
Reduction in fever compared with the mock-treated
infected group
Yes No Yes No Fig. 2
Reduction in combined sneezing & nasal discharge
compared
with the mock-treated infected group
Yes Yes No No Fig. 3
Reduction in cells in nasal wash compared with the
mock-treated infected group
Yes Yes Yes Yes Table 1
Reduction of infectivity in nasal washes on day
2 compared with the mock-treated infected group
Yes (and on day 4) Yes Yes Yes Fig. 4
Reduction of infectivity in nasal washes on day
4 compared with the oseltamivir-treated
infected group
Yes Yes No No Fig. 4
Reduction of infectivity in nasal washes on day
6 compared with the oseltamivir-treated
infected group




Enhancement of 244 DI RNA in nasal washes From day 2; maximum
mean
increase 25,000-fold
Yes 244 RNA absent N/a Fig. 5
Development of A/Cal-speciﬁc HI antibody Yes Yes Yes Yes Table 2
N.J. Dimmock et al. / Antiviral Research 96 (2012) 376–385 383values of 0.02 and 0.04 for treatment with 244 DI virus or oseltam-
ivir, respectively (Fig. 2b). There was no statistical difference in the
day 3 temperatures in infected ferrets treated with 244 DI virus or
oseltamivir (p = 0.32).3.3. 244 DI virus but not oseltamivir reduces respiratory disease
(sneezing and nasal discharge) in infected ferrets
Ferrets were monitored for sneezing and nasal discharge, both
typical respiratory signs of inﬂuenza. Analysis of data collected
twice daily (morning and afternoon) over the 14-day duration of
the study showed that treatment with 244 DI virus signiﬁcantly
(p = 0.009) reduced the score compared with the infected A/Cal
control group by 1.7-fold (Fig. 3). Oseltamivir treatment gave no
signiﬁcant reduction in respiratory disease (Fig. 3). Infected ferrets
treated with 244 DI virus had signiﬁcantly fewer combined clinical
signs (1.6-fold) than those treated with oseltamivir. There was no
difference in the time of respiratory disease between the 244 DI
virus-treated group and the oseltamivir-treated group.3.4. 244 DI virus and oseltamivir reduce cellular inﬁltration into the
nose of infected ferrets
The appearance of a cell inﬁltrate in nasal washes is a general
response to respiratory infection in ferrets. On day 2 the inﬂux of
cells in control A/Cal-infected animals was signiﬁcantly reduced
5-fold by treatment with 244 DI virus and 9.6-fold by oseltamivir
(Table 1). On day 3 cell inﬂux was again signiﬁcantly reduced
1.8-fold by 244 DI virus and 10.7-fold by oseltamivir. However, de-
spite the apparently higher reduction by oseltamivir, the outcome
of the two treatments did not differ signiﬁcantly (Table 1). By day 4
cell inﬁltration had increased in all groups to a similar level,
approximately 100-fold above background. This remained at a pla-
teau for around 8–10 days and then slowly decreased. Cell levels
were still elevated by approximately 10-fold on day 14 when the
study was terminated, although the level in the 244 DI virus-trea-
ted infected ferrets was 2.5-fold lower than in oseltamivir-treated
infected animals (Table 1).3.5. 244 DI virus and oseltamivir reduce nasal wash infectivity in
infected animals compared to control A/Cal-infected ferrets
Infectious virus in the control A/Cal-infected group was just
above background on day 1 after infection, and by day 2 had in-
creasedbymore than100-fold to105.6 ffuper ferret (Fig. 4a). The lev-
els of infectious virus detected on day 2 in the 244 DI virus-treated,
infected groupwas 62-fold lower, and the oseltamivir-treated group
was 200-fold lower (Fig. 4b). The difference between infectivity ti-
tres in the 244 DI virus-treated and infected group and the oseltam-
ivir-treated and infected group was not signiﬁcant. On day 4 the
infectivity titre in the 244DI virus-treated infected groupwas 6-fold
lower than in the oseltamivir-treated infected groups on day 4
(p = 0.04; Fig. 4c). Titres began to fall from day 4 and by day 6 those
in the 244DI virus-treated infected groupand theuntreated infected
group had fallen to 103.4 and 103.3 ffu per ferret, respectively. How-
ever, on day 6 the infectivity of the oseltamivir-treated infected
group was 123-fold higher than the control infected group
(105.4 ffu per ferret), a highly signiﬁcant difference (p = 0.004;
Fig. 4d). All ﬁve animals in the oseltamivir treated group had high ti-
tres of infectious inﬂuenza virus. The possibility that the inﬂuenza
virus had developed resistance to oseltamivir was investigated by
determining if the virus from the oseltamivir-treated infected group
haddeveloped theH275Y aminoacid change that frequently accom-
panies resistance to oseltamivir. This was not found and the reason
for high infectivity titres and/or slower virus clearance in the pres-
ence of oseltamivir is not known. Infectivity in all groups was unde-
tectable by day 8, showing that 244 DI virus did not compromise
virus clearance or lead to persistence of virus infectivity.
3.6. 244 DI virus RNA in ferret nasal washes
RNA was extracted from the nasal washes above and assayed by
quantitative RT-PCR for the presence of 244 DI RNA, the active
principle responsible for DI virus-mediated protection against dis-
ease caused by inﬂuenza A viruses (Dimmock et al., 2008). Fig. 5a
summarizes the mean values per ferret group per day, and
Fig. 5b show values for individual animals. The data show that
244 DI virus RNA was marginally above detectable levels at 1 day
after infection, and that by day 2 there were high levels of 244
384 N.J. Dimmock et al. / Antiviral Research 96 (2012) 376–385DI virus RNA in infected ferrets treated with 244 DI virus. 244 DI
virus RNA was not detected in the other groups indicating that
244 DI virus RNA is speciﬁc for ferrets inoculated with 244 DI virus.
The 244 DI virus RNA levels increased by nearly 1000-fold between
days 1 and 2, and by over 25,000-fold between days 1 and 3, reach-
ing a peak of 1010.8 copies per ferret. 244 DI virus RNA then steadily
declined reaching a very low level on day 10 and was undetectable
on day 14 after infection. These data demonstrate the ability of the
244 DI virus RNA to be ampliﬁed by the very agent that it is acting
against – in this case A/Cal inﬂuenza virus. The >25,000-fold
expansion factor effectively augments the applied dose of 244 DI
virus RNA from 2 lg to >50 mg per animal.
3.7. Other clinical parameters
In addition to the signs and symptoms described above ferrets
were monitored in the morning and the afternoon for loss of appe-
tite, appearance of diarrhoea, and reduction in activity. None of
these was seen in any group.
3.8. 244 DI virus does not inhibit the development of HI serum
antibody
There was a strong HI antibody response to A/Cal/04/09 (H1N1)
in sera taken at 14 days after infection whether groups had been
treated with 244 DI virus, oseltamivir or were untreated (Table 2).
The titre of 244 DI-treated infected group was signiﬁcantly higher
than the infected group treated with oseltamivir (p = 0.008). Thus
amelioration of infection by 244DI virus appeared to improve rather
than diminish the antibody response to the A/Cal haemagglutinin.
4. Discussion
In this study we compared the effects of treatment with DI virus
and oseltamivir on the course of disease and virus load resulting
from infection with 2009 pandemic inﬂuenza A virus (A/Califor-
nia/04/09) in the ferret. Data summarized in Table 3 show that
DI virus reduced fever, weight loss, respiratory symptoms (sneez-
ing and nasal discharge), the appearance of cells in nasal washes,
and virus load. All this was coincident with a dramatic increase
in DI RNA, presumably due to its ampliﬁcation by A/Cal. It is rea-
sonable to suppose that the beneﬁcial effects are the result of the
action of this augmented population of DI RNA. Augmentation of
244 DI RNA is consistent with the mouse model in which ampliﬁ-
cation of 244 DI virus RNA by various inﬂuenza A viruses has been
documented many times (Dimmock et al., 2008; Scott et al.,
2011a). It is likely that 244 RNA in nasal washes is packaged into
newly synthesised DI virus particles as inﬂuenza RNA either free
or in a ribonucleoprotein structure is susceptible to degradation
by ribonuclease (Duesberg, 1969). Furthermore, new DI RNA is
likely to be present as A/Cal DI particles as little, if any, of the A/
PR8 genomic RNA survives the UV irradiation which is given spe-
ciﬁcally to destroy any infectivity present (see Methods). These
A/Cal DI particles can transmit the antiviral 244 DI virus to other
cells in the respiratory tract, and progressively increase the num-
ber of cells that are able to resist infection through the presence
of DI RNA. Treatment with DI virus did not adversely affect the
clearance of virus infectivity, and DI RNA was cleared from nasal
secretions at a similar rate. The role of interferon in protection of
ferrets from A/Cal was not investigated. Studies in mice showed
that active DI virus given intranasally in the absence of infectious
virus stimulates production of interferon type I in the lung, and
that the UV-inactivated DI virus did not stimulate detectable inter-
feron type I in the lung. However, use of interferon receptor knock-
out mice showed that interferon was not required for protection
against type A inﬂuenza virus (Dimmock et al., 2008), but did pro-tect mice from pneumonia virus of mice and an inﬂuenza B virus
(Easton et al., 2011; Scott et al., 2011b). UV-inactivated DI virus
did not protect, and thus does not induce interferon type I.
Oseltamivir treatment was also beneﬁcial although it did not
cause any signiﬁcant decrease in weight loss or respiratory disease
whencompared to the infectedanimals thatwerenot givenanyother
treatment. Oseltamivir reducedvirus load onday2, but the virus load
in oseltamivir-treated animals was more than 100-fold greater than
the virus control on day 6. This differential appears consistent with
a viral reboundobserved following the cessation of oseltamivir treat-
ment in people infected with pandemic 2009 virus (Lee et al., 2011).
We also examined virus from oseltamivir-treated ferrets on day 6 by
sequencing for theH275Ymutation that is associatedwith resistance
to oseltamivir (Ives et al., 2002) but this mutation was not found
(unpublished data). The H275Y mutation was also absent from re-
bound virus in the oseltamivir-treated human cohort (Lee et al.,
2011).Wesurmise that the reboundvirusmay result fromthe release
of progeny virus that hadbefore beenbound to cell receptors because
of the inhibition of viral neuraminidase activity by oseltamivir.
All ferrets developed A/Cal-speciﬁc, serum HI antibody, but there
was signiﬁcantly less in the oseltamivir-treated infected group than
in the DI virus treated infected group. In addition to the signs and
symptoms described above ferrets were monitored in the morning
and the afternoon for loss of appetite, appearance of diarrhoea,
and reduction in activity. None of these was seen in any group.
We conclude that treatment of ferrets with 244 DI virus amelio-
rates clinical disease and virus load resulting from infection with
pandemic A/California/04/09 (H1N1) more effectively than did
treatment with oseltamivir. DI virus did not cause virus to become
persistent or delay clearance, and the presence of high levels of HI
antibody in DI-treated, A/Cal-infected animals suggest that ferrets
would be able to resist a repeat dose of virus.
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